Cardio-oncology

How new targeted cancer therapies and precision medicine can inform cardiovascular discovery

Andrew M. Bellinger, Carlos L. Arteaga, Thomas Force, Benjamin D. Humphreys, George D. Demetri, Brian J. Druker, Javid J. Moslehi

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Cardio-oncology (the cardiovascular care of cancer patients) has developed as a new translational and clinical field based on the expanding repertoire of mechanism-based cancer therapies. Although these therapies have changed the natural course of many cancers, several may also lead to cardiovascular complications. Many new anticancer drugs approved over the past decade are "targeted" kinase inhibitors that interfere with intracellular signaling contributing to tumor progression. Unexpected cardiovascular and cardiometabolic effects of patient treatment with these inhibitors have provided unique insights into the role of kinases in human cardiovascular biology. Today, an ever-expanding number of cancer therapies targeting novel kinases and other specific cellular and metabolic pathways are being developed and tested in oncology clinical trials. Some of these drugs may affect the cardiovascular system in detrimental ways and others perhaps in beneficial ways. We propose that the numerous ongoing oncology clinical trials are an opportunity for closer collaboration between cardiologists and oncologists to study the cardiovascular and cardiometabolic changes caused by the modulation of these pathways in patients. In this regard, cardio-oncology represents an opportunity and a novel platform for basic and translational investigation and can serve as a potential avenue for optimization of anticancer therapies and for cardiovascular research and drug discovery.

Original languageEnglish (US)
Pages (from-to)2248-2258
Number of pages11
JournalCirculation
Volume132
Issue number23
DOIs
StatePublished - Dec 8 2015

Fingerprint

Precision Medicine
Phosphotransferases
Neoplasms
Clinical Trials
Therapeutics
Cardiovascular Agents
Drug Discovery
Cardiovascular System
Metabolic Networks and Pathways
Pharmaceutical Preparations
Patient Care
Research

Keywords

  • cardiotoxicity
  • drug evaluation
  • molecular targeted therapy
  • pre-eclampsia
  • protein-tyrosine kinases
  • translational medical research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Bellinger, A. M., Arteaga, C. L., Force, T., Humphreys, B. D., Demetri, G. D., Druker, B. J., & Moslehi, J. J. (2015). Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation, 132(23), 2248-2258. https://doi.org/10.1161/CIRCULATIONAHA.115.010484

Cardio-oncology : How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. / Bellinger, Andrew M.; Arteaga, Carlos L.; Force, Thomas; Humphreys, Benjamin D.; Demetri, George D.; Druker, Brian J.; Moslehi, Javid J.

In: Circulation, Vol. 132, No. 23, 08.12.2015, p. 2248-2258.

Research output: Contribution to journalReview article

Bellinger, AM, Arteaga, CL, Force, T, Humphreys, BD, Demetri, GD, Druker, BJ & Moslehi, JJ 2015, 'Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery', Circulation, vol. 132, no. 23, pp. 2248-2258. https://doi.org/10.1161/CIRCULATIONAHA.115.010484
Bellinger, Andrew M. ; Arteaga, Carlos L. ; Force, Thomas ; Humphreys, Benjamin D. ; Demetri, George D. ; Druker, Brian J. ; Moslehi, Javid J. / Cardio-oncology : How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. In: Circulation. 2015 ; Vol. 132, No. 23. pp. 2248-2258.
@article{68bd1498f9974cebafd1bc6155e37b1e,
title = "Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery",
abstract = "Cardio-oncology (the cardiovascular care of cancer patients) has developed as a new translational and clinical field based on the expanding repertoire of mechanism-based cancer therapies. Although these therapies have changed the natural course of many cancers, several may also lead to cardiovascular complications. Many new anticancer drugs approved over the past decade are {"}targeted{"} kinase inhibitors that interfere with intracellular signaling contributing to tumor progression. Unexpected cardiovascular and cardiometabolic effects of patient treatment with these inhibitors have provided unique insights into the role of kinases in human cardiovascular biology. Today, an ever-expanding number of cancer therapies targeting novel kinases and other specific cellular and metabolic pathways are being developed and tested in oncology clinical trials. Some of these drugs may affect the cardiovascular system in detrimental ways and others perhaps in beneficial ways. We propose that the numerous ongoing oncology clinical trials are an opportunity for closer collaboration between cardiologists and oncologists to study the cardiovascular and cardiometabolic changes caused by the modulation of these pathways in patients. In this regard, cardio-oncology represents an opportunity and a novel platform for basic and translational investigation and can serve as a potential avenue for optimization of anticancer therapies and for cardiovascular research and drug discovery.",
keywords = "cardiotoxicity, drug evaluation, molecular targeted therapy, pre-eclampsia, protein-tyrosine kinases, translational medical research",
author = "Bellinger, {Andrew M.} and Arteaga, {Carlos L.} and Thomas Force and Humphreys, {Benjamin D.} and Demetri, {George D.} and Druker, {Brian J.} and Moslehi, {Javid J.}",
year = "2015",
month = "12",
day = "8",
doi = "10.1161/CIRCULATIONAHA.115.010484",
language = "English (US)",
volume = "132",
pages = "2248--2258",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Cardio-oncology

T2 - How new targeted cancer therapies and precision medicine can inform cardiovascular discovery

AU - Bellinger, Andrew M.

AU - Arteaga, Carlos L.

AU - Force, Thomas

AU - Humphreys, Benjamin D.

AU - Demetri, George D.

AU - Druker, Brian J.

AU - Moslehi, Javid J.

PY - 2015/12/8

Y1 - 2015/12/8

N2 - Cardio-oncology (the cardiovascular care of cancer patients) has developed as a new translational and clinical field based on the expanding repertoire of mechanism-based cancer therapies. Although these therapies have changed the natural course of many cancers, several may also lead to cardiovascular complications. Many new anticancer drugs approved over the past decade are "targeted" kinase inhibitors that interfere with intracellular signaling contributing to tumor progression. Unexpected cardiovascular and cardiometabolic effects of patient treatment with these inhibitors have provided unique insights into the role of kinases in human cardiovascular biology. Today, an ever-expanding number of cancer therapies targeting novel kinases and other specific cellular and metabolic pathways are being developed and tested in oncology clinical trials. Some of these drugs may affect the cardiovascular system in detrimental ways and others perhaps in beneficial ways. We propose that the numerous ongoing oncology clinical trials are an opportunity for closer collaboration between cardiologists and oncologists to study the cardiovascular and cardiometabolic changes caused by the modulation of these pathways in patients. In this regard, cardio-oncology represents an opportunity and a novel platform for basic and translational investigation and can serve as a potential avenue for optimization of anticancer therapies and for cardiovascular research and drug discovery.

AB - Cardio-oncology (the cardiovascular care of cancer patients) has developed as a new translational and clinical field based on the expanding repertoire of mechanism-based cancer therapies. Although these therapies have changed the natural course of many cancers, several may also lead to cardiovascular complications. Many new anticancer drugs approved over the past decade are "targeted" kinase inhibitors that interfere with intracellular signaling contributing to tumor progression. Unexpected cardiovascular and cardiometabolic effects of patient treatment with these inhibitors have provided unique insights into the role of kinases in human cardiovascular biology. Today, an ever-expanding number of cancer therapies targeting novel kinases and other specific cellular and metabolic pathways are being developed and tested in oncology clinical trials. Some of these drugs may affect the cardiovascular system in detrimental ways and others perhaps in beneficial ways. We propose that the numerous ongoing oncology clinical trials are an opportunity for closer collaboration between cardiologists and oncologists to study the cardiovascular and cardiometabolic changes caused by the modulation of these pathways in patients. In this regard, cardio-oncology represents an opportunity and a novel platform for basic and translational investigation and can serve as a potential avenue for optimization of anticancer therapies and for cardiovascular research and drug discovery.

KW - cardiotoxicity

KW - drug evaluation

KW - molecular targeted therapy

KW - pre-eclampsia

KW - protein-tyrosine kinases

KW - translational medical research

UR - http://www.scopus.com/inward/record.url?scp=84949471785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949471785&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.115.010484

DO - 10.1161/CIRCULATIONAHA.115.010484

M3 - Review article

VL - 132

SP - 2248

EP - 2258

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 23

ER -